Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Oxford based CEO’ operating in the Genetics space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Gordon Sanghera
Chief Executive Officer, Co – founder of Oxford Nanopore Technologies
Gordon Sanghera was co-founder of Oxford Nanopore, together with Hagan Bayley and IP Group. He was appointed CEO in June 2005 having acted as a consultant since February 2005 whilst the Company was established. He brings over 15 years experience in the design, development and global launch of novel point-of-care biosensor devices. At Abbott Laboratories, Dr Sanghera held both UK and US Director level positions, including Research Director and Manufacturing Process Development Director. Before its acquisition by Abbott, Gordon led the R&D of Medisense Inc. where he was instrumental in the launch of several generations of blood glucose biosensor systems for the consumer and medical markets. He has also developed and validated market production processes to meet with the regulatory requirements for USA and Europe. Gordon has a DPhil in biosensor technology and a degree in Chemistry.
Follow Gordon Sanghera:
About Oxford Nanopore Technologies: Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.
Ian Nicholson
Chief Executive Officer of F2G
Ian joined Advent in 2012 from Chroma Therapeutics Limited, a privately held oncology-focussed R&D company, where he served as Chief Executive Officer for eight years. Prior to joining Chroma, Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK’s largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. Ian has held a variety of senior commercial positions with Oxford Asymmetry International plc, Lonza AG and Amersham International plc and currently sits on the Boards of Consort Medical plc, Clinigen Group plc and is Non-Executive Chairman of Bioventix plc. Ian holds a B.Sc. (Hons.) degree from University College London and an MBA from Boston University. Ian is CEO of F2G Ltd and an advisor to NeRRe Therapeutics.
Follow Ian Nicholson:
About Advent Life Sciences, Amersham International, F2G: F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
Dr. Danuta Jeziorska
CEO & Co-Founder of Nucleome Therapeutics
Danuta Jeziorska is the CEO & Co-Founder at Nucleome Therapeutics.
Follow Dr. Danuta Jeziorska:
About Nucleome Therapeutics: Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Dr. Danuta Jeziorska
CEO & Co-Founder of Nucleome Therapeutics
Danuta Jeziorska is the CEO & Co-Founder at Nucleome Therapeutics.
Follow Dr. Danuta Jeziorska:
About Nucleome Therapeutics: Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Malcolm Pye
CEO of Benchmark Holdings
Mr. Malcolm David Foster Pye has been the Chief Executive Officer at Benchmark Holdings plc since November 2000. Mr. Pye works within Benchmark Holdings companies on strategic business development, marketing, acquisitions and commercial matters and his roles include the development of the important synergies between Benchmark Holdings companies and ensuring that opportunities are resourced and exploited. He has over 30 years’ experience in international agribusiness, including at board director level within the Hillsdown Holdings/HMTF animal breeding, feed milling, veterinary and poultry companies prior to joining Ruth Layton and Roland Bonney to set up the Group. During his time at Hillsdown he also worked extensively on M&A projects, both leading and advising on acquisitions and disposals. Mr. Pye serves as Executive Director at Benchmark Holdings plc. Mr. Pye is a graduate of the University of Wales (Bangor) in Zoology/Applied Zoology.
Follow Malcolm Pye:
About Benchmark Holdings: Benchmark Holdings, a pioneering bioagtech company.
Lukas Lange
CEO and Co-Founder of Probably Genetic
Follow Lukas Lange:
About Probably Genetic: Probably Genetic helps rare genetic disease patients.
Peter Donnelly
Chief Executive Officer of Genomics
Peter Donnelly is Director of the Wellcome Trust Centre for Human Genetics and Professor of Statistical Science at the University of Oxford, and a founder and director of Genomics plc, a fast-growing company in the genome analytics space. He has played a leading role in many of the major projects and developments at the interface between genetics, healthcare, and clinical medicine, including the HapMap project, the Wellcome Trust Case Control consortia, and WGS500, one of the studies pioneering whole genome sequencing in clinical medicine.
Follow Peter Donnelly:
About Genomics, University of Oxford: Genomics plc aiming to lead the genomic transformation of healthcare.
Samantha Decombel
Co-Founder & CEO of FitnessGenes
A co-founder of FitnessGenes, with a PhD in genetics and a passion for science communication, Sam is responsible for product development and management of the science team. Fascinated by genetics from an early age, she studied the subject for her PhD at the University of Birmingham, UK, where she has also lectured on Evolutionary and Conservation Genetics. Sam is an enthusiastic sportswoman, and particularly enjoys playing football and running when she is not in the gym trying to improve on her squat PB of 165lb.
Follow Samantha Decombel:
About FitnessGenes, InnovationXchange, Play DNA: FitnessGenes is pioneering the field of genetic data analysis to produce personalized fitness and diet recommendations.
